NCT03498326View on ClinicalTrials.gov

Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2030

Conditions
Pancreatic CancerChemotherapy Effect
Interventions
DRUG

Gemcitabine

One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.

DRUG

Gemcitabine

the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.

Trial Locations (1)

310009

RECRUITING

the second affiliated hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER